SNY Stock Analysis: Buy, Sell, or Hold?
SNY - Sanofi American Depositary Shares (Each representing one-half of one ordinary share)
$45.85
0.70 (1.55%)
▲
5d:
+4.87%
30d:
+5.74%
90d:
+2.07%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Jul 30, 2026
0d
Get Alerted When SNY Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: SNY shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: SNY shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$62.97
Based on 6.2% avg growth
INTRINSIC VALUE TODAY
$39.10
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.7x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: SNY is currently trading at $45.85, which is considered extended relative to its 30-day fair value range of $43.04 to $44.79. The stock's valuation (Forward PE: 8.4) is in line with its historical norms (8.7). Remarkably, the market is currently pricing in an annual earnings decline of 1.1% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, SNY is in a downtrend. The price is approaching resistance at $46.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNY scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.72 (+19.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, SNY is in a downtrend. The price is approaching resistance at $46.11. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: SNY scores 20/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $53.72 (+19.5%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$43.04 -
$44.79
Company Quality Score
34/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
26.2%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (20/100)
- BULLISH: High volume confirmation
- BULLISH: Trading below Wall St target ($53.72)
- WARNING: Composite score 34/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$43.04 -
$44.79
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$43.24
Resistance Level
$46.11
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
8.39
Wall Street Target
$53.72
(+19.5%)
Revenue Growth (YoY)
14.6%
Earnings Growth (YoY)
-91.2%
Profit Margin
8.1%
Valuation Discount vs History
-1.1% cheaper
PE vs Historical
8.4 vs 8.7
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.1%
(market-implied from PE analysis)
1-Year Target
$44.48
(-1%)
2-Year Target
$43.99
(-2%)
3-Year Target
$43.50
(-3%)
3-Yr Target (if PE normalizes)
(PE: 8→9)
$45.12
(+0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 8.4%)
$137.38
(+206%)
Base:
(SPY PE: 8.4, Growth: 8.4%)
$57.31
(+27%)
Bear:
(PE: 7.1, Growth: 8.4%)
$48.71
(+8%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (23x PE), but valuation improves significantly next year (8x PE) as earnings recover.
Trailing PE: 23.37 | Current EPS (TTM): $1.90
Bull Case
$97.70
(+113%)
Analyst growth 100.0%, PE expands to 25.7
Base Case
$88.82
(+94%)
Market implied 100.0%, PE stable at 23.4
Bear Case
$30.20
(-34%)
Severe decline -20.0%, PE contracts to 19.9
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 8.4 to 8.7
Stabilization Target:
$46.64
(+3.7%)
PE Expansion Potential:
+3.7%
Share & Embed Analysis
Last updated: August 24, 2026 8:19 AM ET
Data refreshes hourly during market hours. Next update: 9:19 AM
Data refreshes hourly during market hours. Next update: 9:19 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SNY showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1315 | 37 SELL |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$157 | 34 SELL |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$277 | 41 HOLD |
|
BIIB
Biogen Inc |
HOLD
37 analysts |
$236 | 42 HOLD |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$388 | 38 SELL |
